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ABSTRACT
The existence of long-lived HIV-1-infected resting memory CD4 T cells is thought to be the primary obstacle to HIV-1 eradica-
tion. In the search for novel therapeutic approaches that may reverse HIV-1 latency, inhibitors of histone deacetylases (HDACis)
have been tested to reactivate HIV-1 replication with the objective of rendering HIV-1-infected cells susceptible to elimination
either by HIV-specific CD8 T cells or through virus-mediated cytopathicity. In the present study, we evaluated the efficiency of
HDACis to reactivate HIV-1 replication from resting memory CD4 T cells isolated from aviremic long-term-treated HIV-1-in-
fected subjects. We demonstrate that following prolonged/repeated treatment of resting memory CD4 T cells with HDACis,
HIV-1 replicationmay be induced from primary resting memory CD4 T cells isolated from aviremic long-term-treated HIV-1-
infected subjects. More importantly, we demonstrate that HIV-1 reactivated in the cell cultures was not only replication compe-
tent but also infectious. Interestingly, givinostat, an HDACi that has not been investigated in clinical trials, was more efficient
than vorinostat, panobinostat, and romidepsin in reversing HIV-1 latency in vitro. Taken together, these results support further
evaluation of givinostat as a latency-reversing agent (LRA) in aviremic long-term-treated HIV-1-infected subjects.
IMPORTANCE
Themajor barrier to HIV cure is the existence of long-lived latently HIV-1-infected resting memory CD4 T cells. Latently HIV-1-
infected CD4 T cells are transcriptionally silent and are therefore not targeted by conventional antiretroviral therapy (ART) or
the immune system. In this context, one strategy to target latently infected cells is based on pharmacological molecules that may
force the virus to replicate and would therefore render HIV-1-infected cells susceptible to elimination either by HIV-specific
CD8 T cells or through virus-mediated cytopathicity. In this context, we developed an experimental strategy that would allow
the evaluation of latency-reversing agent (LRA) efficiency in vitro using primary CD4 T cells. In the present study, we demon-
strate that HDACis are potent inducers of replication-competent and infectious HIV-1 in resting memory CD4 T cells of long-
term ART-treated patients and identify givinostat as the most efficient LRA tested.
The existence of long-lived HIV-1-infected resting memoryCD4 T cells represents the primary obstacle to HIV-1 eradica-
tion (1–6). In this regard, it has been hypothesized that latency-
reversing agents (LRAs) that may reactivate HIV-1 replication
from latently infected cells may render HIV-1-infected cells sus-
ceptible to elimination either by HIV-specific CD8 T cells or
through virus-mediated cytopathicity (7). The use of in vitromod-
els of HIV-1 latency has contributed to evaluate LRA efficiency in
the reactivation of HIV-1 replication (8–14). However, such types
of assays also face some limits inherent in the clonality of the
HIV-1 integration site (8–11) or the frequency of latently infected
cells (11–14). To circumvent this caveat, several groups have eval-
uated the efficiency of LRAs on primary resting CD4 T cells using
various strategies, including the “classical,” “modified,” or “en-
hanced” viral outgrowth assay (VOA) (15–17).
Using a modified version of the “classical” VOA, David Marg-
olis’ group first showed that valproic acid induced outgrowth of
HIV from resting CD4 T cells of aviremic patients at concentra-
tions achievable in vivo, thus demonstrating that histone deacety-
lase inhibitors (HDACis) could reactivate HIV-1 replication from
resting CD4 T cells in vitro (17). More recently, John Mellors’ and
Robert Siliciano’s groups have evaluated the efficiency of LRAs on
primary resting memory CD4 T cells and have underscored the
difficulty of reactivating HIV-1 replication in primary resting
memory CD4 T cells (15, 16). On the basis of these results, it was
concluded that HDACis may have limited effectiveness in the re-
activation of replication-competent HIV-1 in primary resting
memory CD4 T cells (15), unless a combination of mechanisti-
cally distinct LRAs is used (18).
The relative lack of efficacy of LRAs to reactivate HIV-1 repli-
cation in vitro contrasts with the findings of clinical studies show-
ing promising results on the ability of HDACis (via single-dose or
multidose administration) such as vorinostat, romidepsin, and
panobinostat to increase cell-associated RNA and more impor-
tantly to induce transient blips in viremia in otherwise aviremic
antiretroviral therapy (ART)-treated subjects (19, 20, 31). In ad-
dition, a recent study from Dar et al. postulated that increasing
baseline transcription noise can enhance the probability of suc-
cessful viral release from HIV-infected cells (21). In this context,
we hypothesized that repeated/prolonged treatment of resting
memory CD4 T cells with HDACis in the presence of increased
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baseline transcription noise may reactivate HIV-1 replication
from primary resting memory CD4 T cells isolated from aviremic
long-term-treated HIV-1-infected subjects.
Therefore, in the present study, we used a modified VOA that
integrates a number of strategies that may potentiate the thera-
peutic effects of HDACis and create better experimental condi-
tions for amplification of HIV-1 replication in vitro. These include
(i) increased duration of treatment of resting memory CD4 T cells
with HDACis to mimic the regimens associated with the better
therapeutic effects of these drugs when administered to patients
and (ii) use of allogeneic (irradiated or not) CD8-depleted blood
mononuclear cells from HIV-1-uninfected subjects that may pro-
vide large numbers of novel CD4 T-cell targets to amplify HIV-1
replication in vitro and/or increase baseline transcription noise,
which in turn may enhance the probability of successful viral re-
lease from cells exposed to HDACis (21).
We demonstrate that following prolonged/repeated treatment
of resting memory CD4 T cells with HDACis, HIV-1 replication
can be induced from primary resting memory CD4 T cells isolated
from aviremic long-term-treated HIV-1-infected subjects. The
use of allogeneic nonirradiated blood mononuclear cells appears
to have a secondary effect since it was associated only with a minor
effect on HIV-1 replication. More importantly, we demonstrate
that HIV-1 reactivated in the cell cultures was not only replication
competent but also infectious. Interestingly, givinostat, an
HDACi that has not been investigated in clinical trials, was more
efficient than vorinostat, panobinostat, and romidepsin in revers-
ing HIV-1 latency in vitro.
MATERIALS AND METHODS
Ethics statement. The present study was approved by the Institutional
Review Board of Lausanne University Hospital, University of Lausanne
(i.e., Centre Hospitalier Universitaire Vaudois), and all subjects gave writ-
ten informed consent.
Study group, ethics statement, and cell isolation. Ten HIV-1-in-
fected adult volunteers (Table 1) and six HIV-uninfected subjects were
enrolled in the present study. No statistical method was used to predeter-
mine the sample size. The sample size was estimated based on a previously
published study (15). As inclusion criteria, only patients under antiretro-
viral therapy for more than 2 years with undetectable HIV-1 viremia (20
HIV-1 RNA copies/ml) were enrolled in the study. As exclusion criteria,
patients experiencing blips of viremia (50 HIV-1 RNA copies per ml of
plasma) within the last 12 months were not enrolled. Leukapheresis and
blood samples were obtained at the local blood bank (Centre de Transfu-
sion Sanguine [CTS], Lausanne, Switzerland). Blood mononuclear cells
were isolated as previously described (22). Since the inclusion criteria
were the same for the 10 patients studied, there was no need for random-
ization or blinding.
Reagents and cell culture. Vorinostat (Merck Research Laboratory,
USA), romidepsin (Cellgene, USA), panobinostat (Novartis, Switzer-
land), givinostat (Italfarmaco; Italy), belinostat (Topotarget and Spec-
trum Pharmaceuticals, Denmark), and bryostatin were obtained from
Hölzel Diagnostika (Germany) and resuspended in dimethyl sulfoxide
(DMSO). Cells were cultured in RPMI (Gibco, Life Technologies) con-
taining 10% heat-inactivated fetal bovine serum (FBS) (Institut de Bio-
technologies Jacques Boy), 100 IU/ml penicillin, and 100 g/ml strepto-
mycin (Bio Concept).
Antibodies. The following antibodies were used. Allophycocyanin
(APC)-H7-conjugated anti-CD3 (clone SK7), peridinin chlorophyll pro-
tein (PerCP)-Cy5.5-conjugated anti-CD8 (clone SK1), Pacific Blue (PB)-,
fluorescein isothiocyanate (FITC)-, or phycoerythrin (PE)-CF594-conju-
gated anti-CD4 (clone RPA-T4), V450-conjugated anti-HLA-DR (clone
G46-6), PE-Cy7-conjugated anti-CD25 (clone M-A251), PerCP-Cy5.5-
conjugated anti-CD69 (clone L78), purified coating anti-CD3 (clone
UCHT1), and anti-CD28 (clone CD28.2) monoclonal antibodies (MAbs)
were purchased from BD (Becton Dickinson, USA) or from Biolegend
(Switzerland). PE-conjugated anti-acetyl H3 and H4 were from Merck
Millipore (USA), and electron-coupled dye (ECD)-conjugated anti-
CD45RA (clone 2H4) was from Beckman Coulter (USA).
Flow cytometry. Data were acquired on a 4-laser LSR Sorp flow cy-
tometer (405, 488, 532, and 633 nm) and were analyzed using FlowJo
v9.4.11 (Treestar, Inc., Ashland, OR). At least 100,000 events were ac-
quired for each sample.
Sorting of restingmemory CD4 T cells. Cryopreserved blood mono-
nuclear cells were thawed, and CD4 T cells were enriched using EasySep
human CD4 T-cell enrichment kit (StemCell Technologies, USA). CD4 T



































1 47 M 5 760 20 5 ETR, FTC, TDF 33 4.17 0.35
5 41 F 9 1,370 20 6 TDF, FTC, ATV/r 5,951 29 0.77
6 51 M 6 391 20 6 FTC, TDF, ETV 7 0.35 0.35
7 36 M 6 760 20 3 ABC, 3TC, ATV/r 1,765 2.05 0.35
8 41 M 15 323 20 6 ABC, 3TC, EFV 1,170 5.13 0.35
10 49 M 8 543 20 8 TDF, FTC, EFV 958 39.39 1.19
12 29 F 8 473 20 2 ABC, 3TC, DRV/r 1,179 4.28 0.35
14 37 M 6 1,267 20 2 TDF, FTC, EFV 972 29 0.77
16 49 M 25 549 20 2 ABC, 3TC, EFV 14,309 16.47 1.31
18 45 M 3 376 20 2 TDF, FTC, EFV 2,074 1.81 0.35
a HAART, highly active antiretroviral therapy.
b ETR, etravirine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; ATV/r, atazanavir boosted with ritonavir; 3TC, lamivudine; ABC, abacavir; DRV/r, darunavir boosted
with ritonavir; EFV, efavirenz.
c Designated “RUPM” in the text and selected figures.
d Designated “IUPM” in the text and selected figures.
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cells were then stained with an Aqua LIVE/DEAD stain kit (4°C, 15 min)
and then with anti-CD4 –FITC, anti-CD45RA–ECD, anti-HLA-DR–PB,
anti-CD25–PE-Cy7, and anti-CD69 –PerCp-Cy5.5 (4°C, 25 min) and vi-
able resting memory (CD4CD45RACD25CD69HLA-DR) CD4
T-cell populations were sorted using a FACSAria fluorescence-activated
cell sorter (Becton Dickinson). In all sorting experiments, the grade of
purity of the sorted cell populations was97%.
Integrated HIV-1 DNA quantification. Resting memory CD4 T cells
were sorted as described above and lysed using lysis buffer (10 mM Tris-
HCl, pH 8.0, 50 nM KCl, 400 g/ml proteinase K [Invitrogen]), and
integrated HIV-1 DNA and CD3 gene copy numbers were determined
using a cross-clade ultrasensitive nested Alu PCR, as previously described
(23). The frequency of HIV-1 integrated DNA per million cells was cal-
culated as previously described (23).
Modified viral outgrowth assay. Different cell concentrations (5-fold
limiting dilutions of 5  105, 105, 2  104, and 4  103 cells) of sorted
viable resting memory CD4 T cells (CD4 CD45RA CD25 CD69
HLADR) from HIV-1-infected subjects (Table 1) were cultured (5
replicates per condition) in complete RPMI with allogeneic fresh CD8-
depleted blood mononuclear cells (106 cells/ml) from HIV-uninfected
subjects in the presence or absence (negative control) of an HDACi: i.e.,
vorinostat (400 nM), romidepsin (5 nM), panobinostat (15 nM), givinos-
tat (400 nM), or belinostat (400 nM). As a positive control, cells were
stimulated for 3 days with anti-CD3/CD28 MAb-coated plates (10 g/
ml). In some experiments, sorted viable resting memory CD4 T cells from
HIV-1-infected subjects were exposed to (i) givinostat (400 nM) and/or
bryostatin (10 nM) for 18 h or (ii) givinostat (400 nM) for 14 days and/or
anti-CD3/CD28 MAbs. In some experiments, allogeneic CD8-depleted
peripheral blood mononuclear cells (PBMCs) from HIV-1-negative sub-
jects were irradiated (40 Gy) or replaced by autologous irradiated (40 Gy)
CD8-depleted PBMCs or allogeneic irradiated (40 Gy) CD8-depleted PB-
MCs. All cell conditions involved culture in complete RPMI supple-
mented with interleukin-2 (IL-2) (50 U/ml) and IL-7 (10 ng/ml) for 14
days. Medium was replaced at day 5 and resupplemented with HDACi and
cytokines. Supernatants were collected at day 14. The presence of P24
antigen was assessed by ECL Cobas HIV Ag (Roche; Switzerland). One
enhanced chemiluminescence (ECL) unit corresponds to about 22 pg/ml.
The presence of HIV-1 RNA was assessed by the Cobas AmpliPrep/Taq-
Man HIV-1 test (Roche, Switzerland) or by the Abbott RealTime HIV-1
assay (Abbott, USA) following 1/10 medium dilution in basement matrix
buffer (Ruwag Handels AG). The numbers of replication-competent units
per million cells (RUPM) (24) and infectious units per million cells
(IUPM) (15) were calculated by conventional limiting dilution methods
using extreme limiting dilution analysis (http://bioinf.wehi.edu.au
/software/elda/) (25).
In vitro HIV-1 infection assay. CD8-depleted blood mononuclear
cells isolated from HIV-uninfected donors were activated for 48 h with
anti-CD3/CD28 microbeads (Miltenyi) in complete RPMI medium sup-
plemented with IL-2 (50 U/ml). Activated allogeneic CD8-depleted blood
mononuclear cells (106 cells/ml) from HIV-1-uninfected donors were
washed and exposed (6 h, 37°C, 5% CO2) to 100 l P24
 supernatants
collected at day 14 following various modified VOA conditions (anti-
CD3/CD28 MAbs or HDACi treatments). Following 6 h of exposure, cells
were washed twice with complete medium and cultured for an additional
10 days in complete RPMI medium. The presence of infectious HIV-1
particles was determined in the culture supernatants at days 0, 3, and 10
postinoculation as assessed by P24 production assay using ECL.
Assessment of CD4 T-cell viability. CD4 T cells isolated from 3 HIV-
uninfected individuals were exposed or not to vorinostat (400 nM), ro-
midepsin (5 nM), panobinostat (15 nM), givinostat (400 nM), or belinos-
tat (400 nM) in the presence of allogeneic CD8-depleted PBMCs isolated
from HIV-uninfected subjects. After 24, 48, 96, and 144 h, cells were
stained with the Aqua LIVE/DEAD stain kit (4°C, 15 min), washed, and
stained with anti-CD3 APC-H7, anti-CD4-FITC, and annexin V-APC
(4°C, 20 min). Cells were washed with annexin buffer, and the percentages
of CD3 CD4 Aqua and CD3 CD4 annexin cells were assessed by
flow cytometry.
Proliferation inhibition assay. Blood mononuclear cells were stained
with 0.25 M 5,6-carboxyfluorescein succinimidyl ester (CFSE [Molecu-
lar Probes, USA]) as previously described (22) and stimulated for 6 days
with anti-CD3/CD28 MAb-coated plates (10 g/ml), or left unstimu-
lated, in the presence or in the absence of HDACi: vorinostat (400 nM),
romidepsin (5 nM), panobinostat (15 nM), givinostat (400 nM), or beli-
nostat (400 nM). Cells were then washed and stained (30 min, 4°C) with
anti-CD3–APC-H7 and anti-CD4 –PE-CF594, and the percentage of via-
ble cells was assessed using the Vivid LIVE/DEAD stain kit (Invitrogen).
Proliferating CD4 T cells were defined as viable CD3 CD4 CFSElow
cells.
Evaluation of HDACi-induced histone H3 and H4 acetylation.
Freshly isolated blood mononuclear cells were exposed or not to HDACi
(i.e., vorinostat [400 nM], romidepsin [5 nM], panobinostat [15 nM]),
givinostat [400 nM], or belinostat [400 nM]) for 24 h, and histone H3 and
H4 acetylation was assessed as previously described (26). Briefly, cells
were stained with the Aqua LIVE/DEAD stain kit (4°C, 20 min), perme-
abilized (4°C, 1 h) with a Foxp3 fixation/permeabilization kit (eBiosci-
ence), blocked (4°C, 10 min) with FBS, and washed and stained (4°C, 25
min) with anti-CD3–APC-H7, anti-CD8 –PerCp-Cy5.5, anti-CD4 –PB,
and anti-acetyl H3–PE or anti-acetyl H4 –PE. Expression of acetyl histone
H3 and H4 in CD4 T-cell population was assessed by flow cytometry.
Assessment of level of expression of activationmarker and prolifer-
ation capacity of purified resting memory CD4 T cells exposed to allo-
geneic CD8-depleted mononuclear cells. Sorted viable resting memory
CD4 T cells (CD4 CD45RA CD25 CD69 HLADR) from HIV-1-
uninfected subjects (n  3) were labeled with CFSE and cultured with
allogeneic fresh CD8-depleted blood mononuclear cells (106 cells/ml)
from HIV-1-uninfected subjects or remained unexposed (negative con-
trol). As a positive control, cells were stimulated for 3 days with anti-CD3/
CD28 MAb-coated plates (10g/ml). All cell conditions were cultured in
complete RPMI medium supplemented with IL-2 (50 U/ml) and IL-7 (10
ng/ml) for 14 days. At days 0, 1, 2, 3, and 6, cells were washed and stained
(30 min, 4°C) with anti-CD3–APC-H7, anti-CD4 –PE-CF594, anti-HLA-
DR–PB, anti-CD25–PE-Cy7, and anti-CD69 –PerCp-Cy5.5, and the per-
centage of viable cells was assessed using the Vivid LIVE/DEAD stain kit
(Invitrogen). Proliferating CD4 T cells were defined as viable CD3
CD4 CFSElow cells.
Statistical analyses. Statistical significance (P values) was obtained
either using a two-tailed chi-square analysis for comparison of positive
proportions or by one-way analysis of variance (ANOVA) (Kruskal-Wal-
lis test) followed by a Wilcoxon matched-pair two-tailed signed rank test
for multiple comparisons. When required, Bonferroni’s correction was
applied for multiple comparisons. Finally, Spearman’s rank test was used
for correlations.
RESULTS
Experimental strategy to evaluate the efficiency of HDACis to
reverse HIV-1 latency in resting memory CD4 T cells isolated
from long-term-treated HIV-1-infected individuals. The modi-
fied VOA is schematically outlined in Fig. 1A. As a positive con-
trol, resting memory CD4 T cells were stimulated with anti-CD3/
CD28 MAbs for 3 days in the presence of IL-2 and IL-7. The
presence of HIV-1 RNA and P24 in the culture supernatants were
measured using validated diagnostic assays (Fig. 1A). It is impor-
tant to underscore that the concentrations of HDACis used in the
modified VOA assay corresponded to the clinical doses used in
patients. The proportion of responders, proportion of positive
wells, and HIV-1 RNA and P24 levels were generated using the 5
replicates of the lowest dilution of cells (5 105 cells/condition) in
the modified VOA (Fig. 1A), while the limiting dilution format
was used to evaluate the frequencies of inducible replication-com-
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petent virus from latently HIV-1-infected cells. The frequencies of
cells containing replication-competent virus were assessed by (i)
the detection of HIV RNA in VOA supernatants, expressed as
replication-competent RNA units per million (RUPM) (24), and
by (ii) the detection of HIV P24 in VOA supernatants, expressed
as infectious units per million (IUPM) (15) (Fig. 1A).
In preliminary experiments, it was determined whether all the
HDACis tested, including vorinostat, romidepsin, belinostat,
FIG 1 HDACis efficiently reactivate HIV-1 replication from latently infected resting memory CD4 T cells isolated from long-term-treated HIV-1-infected
subjects. (A) Schematic representation of the modified VOA. (B) Proportion of responders to HDACis treatment based on the detection of HIV-1 RNA (n 10;
5 replicates per condition). Individuals having at least one replicate with detectable HIV-1 RNA (200 HIV-1 RNA copies/ml) are indicated as “responders” for
the condition tested. (C) Proportion of responders to HDACi treatment based on the detection of P24 (n 10; 5 replicates per condition). Individuals having
at least one replicate with detectable P24 (1 ECL unit/ml) are indicated as “responders” for the condition tested. (D) Proportion of HIV-1 RNA-positive wells
induced following HDACis treatment (n 10; 5 replicates per condition). Wells with detectable HIV-1 RNA (200 HIV-1 RNA copies/ml) are indicated to as
HIV-1 RNA positive for the condition tested. (E) Proportion of P24-positive wells induced following HDACis treatment (n 10; 5 replicates per condition).
Wells with detectable P24 (1 ECL unit/ml) are indicated as P24 positive for the condition tested. (F) Levels of HIV-1 RNA copies per milliliter induced following
HDACis treatment (n 10; 5 replicates per condition). (G) Levels of P24 (ECL units per milliliter) induced following HDACis treatment (n 10; 5 replicates
per condition). (H and I) Frequencies of inducible replication-competent virus as measured by replication-competent (RNA) units per million (RUPM) (H) or
as measured by infectious units per million (IUPM) (I). (J) Correlation between P24 and HIV-1 RNA levels (n 350; 10 subjects, 7 conditions, 5 replicates per
condition). Panels B to G and J were generated using the 5 replicates of the lowest dilution of cells (5 105 cells) of all conditions by modified VOA. Subjects were
color coded, and each color corresponds to a subject (F to J). Histograms correspond to the mean (B to I), and red error bars correspond to the standard error
of the mean (SEM) (F to I). Blue lines correspond to the median (F to I). Red asterisks indicate statistical significance compared to unstimulated or unexposed
(US) (P 0.05). Green asterisks indicate statistical significance compared to vorinostat (P 0.05). romi, romidepsin; pano, panobinostat; givi, givinostat; beli,
belinostat. Statistical significance (P values) was obtained using two-tailed chi-square analysis for comparison of positive proportions (B to E), by one-way
ANOVA (Kruskal-Wallis test) followed by Wilcoxon matched-pair two-tailed signed rank test (F to I), or by using Spearman’s rank correlations (J). Bonferroni’s
correction was applied for multiple comparisons.
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panobinostat, and givinostat, were functionally active. The results
obtained showed that all HDACis tested significantly increased
acetyl histone H3 and/or H4 mean fluorescent intensity (MFI)
(P  0.05) (Fig. 2A and B) and significantly inhibited T-cell re-
ceptor (TCR)-induced CD4 T-cell proliferation (P  0.05) (Fig.
2C), thus indicating that all HDACis tested were functionally ac-
tive. In addition, the viability of CD4 T cells exposed to clinically
relevant concentrations of HDACis was also assessed by a flow
cytometry-based assay. The results obtained showed that using the
aforementioned VOA experimental strategy, all HDACis tested
did not significantly influence CD4 T-cell viability compared to
that of the unstimulated cells (Fig. 2D and E).
We then evaluated RUPM and IUPM frequencies in 10 avire-
mic long-term-treated patients (duration of treatment, 2 to 8
years; average, 4.2 years) using the VOA after stimulation with
anti-CD3/CD28 MAbs. The cumulative data shown in Fig. 1B
through I and Table 1 showed that anti-CD3/CD28 MAb treat-
ment consistently induced HIV-1 replication, as assessed by
HIV-1 RNA and P24 production in the culture supernatants,
while all replicates (except one at the limit of detection) of the
unstimulated condition remained negative for both HIV-1 RNA
and P24, demonstrating that the use of allogeneic CD8-depleted
blood mononuclear cells from HIV-uninfected subjects in the
presence of IL-2 and IL-7 was not sufficient to induce HIV-1 rep-
lication and confirmed the results obtained by Bosque et al. (27).
In addition, the inducible RUPM and IUPM frequencies mea-
sured in the 10 aviremic long-term-treated HIV-1-infected sub-
jects studied were consistent with the frequencies reported in pre-
vious studies (15, 24). Of note, the use of anti-CD3/CD28 MAbs to
stimulate HIV-1 replication did not underestimate the frequen-
cies of inducible replication-competent virus compared to phyto-
hemagglutin (PHA) stimulation (data not shown).
HDACis efficiently reactivate HIV-1 replication from la-
tently infected resting memory CD4 T cells isolated from long-
term-treated HIV-1-infected subjects. We then evaluated the
ability of vorinostat, romidepsin, belinostat, panobinostat, and
givinostat to reverse HIV-1 latency using the modified VOA in the
10 aviremic long-term-treated subjects (Table 1). The cumulative
data indicated that (i) all of the HDACis tested significantly in-
duced the production of HIV-1 RNA in the culture supernatants
compared to untreated cultures, and (ii) the proportions of re-
sponder subjects (i.e., subjects positive for HIV-1 RNA in the cul-
ture supernatants) were 90% (9 out of 10 subjects) in the cell
cultures treated with vorinostat and romidepsin and 100% in cell
cultures treated with panobinostat, givinostat, belinostat, and
anti-CD3/CD28 (the latter used as the positive control) (P 0.05)
(Fig. 1B and D). Of note, no significant differences were observed
between the different HDACis tested either in the proportion of
subjects with detectable HIV-1 RNA or in the proportion of wells
positive for HIV-1 RNA (P 0.05) (Fig. 1B and D). Notably, the
FIG 2 Assessment of functional activity and toxicity of the HDACis tested. (A and B) Mean fluorescence intensity (MFI) of acetyl histone H3 (A) or histone H4
(B). Blood mononuclear cells isolated from 4 HIV-seronegative individuals were exposed or not (unexposed control [US]) to vorinostat (400 nM), romidepsin
(Romi [5 nM]), panobinostat (Pano [15 nM]), givinostat (Givi [400 nM]), or belinostat (Beli [400 nM]) for 24 h, and acetyl histone H3 or H4 MFI was analyzed
on CD4 T cells by flow cytometry. (C) Percentage of CD4 T-cell proliferation upon HDACi treatment. CFSE-labeled blood mononuclear cells isolated from 3
HIV-seronegative individuals were exposed or not (US) to vorinostat (400 nM), romidepsin (5 nM), panobinostat (15 nM), givinostat (400 nM), or belinostat
(400 nM) for 24 h and stimulated for 6 days with anti-CD3/CD28 MAbs, and the percentage of proliferating CD4 T-cell proliferation (CFSE low) was assessed
by flow cytometry. The percentage of annexin V-positive (D) or Aqua-positive (E) CD4 T cells was assessed at 24, 48, 96, and 144 h.CD4 T cells isolated from 3
HIV-uninfected individuals were exposed or not to vorinostat (400 nM), romidepsin (5 nM), panobinostat (15 nM), givinostat (400 nM), and belinostat (400
nM) in the presence of allogeneic CD8-depleted PBMCs isolated from HIV-uninfected subjects. Red horizontal lines or histograms correspond to the mean, and
red error bars correspond to the SEM. Red asterisks indicate statistical significance (P  0.05) compared to unexposed conditions. Statistical significance (P
values) was obtained using a one-way ANOVA (Kruskal-Wallis test) followed by a paired t test (A to C).
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use of the Roche TaqMan assay did not overestimate the quantity
of HIV-1 RNA present in the culture supernatants, as indicated by
the cross-validation test using the Abbott RealTime HIV-1 assay,
which avoids the potential detection of HIV-1 DNA (28) (Fig. 3).
Indeed, no significant differences (P 0.05) were observed under
any condition tested (HDACi treatment and anti-CD3/CD28
MAbs) between the quantification of HIV-1 RNA using the Roche
TaqMan assay or the Abbott RealTime HIV-1 assay, demonstrat-
ing that the Roche TaqMan assay used in the present study did not
overestimate the quantity of HIV-1 RNA present in the culture
supernatants under the experimental conditions used.
P24 production was also measured in the cell cultures treated
FIG 3 HIV-1 RNA quantification in culture supernatants using Roche TaqMan assay versus the Abbott RealTime HIV-1 assay. Culture supernatants containing
a range of HIV-1 RNAs, induced following HDACi treatments, anti-CD3/CD28 MAb treatment, givinostat plus anti-CD3/CD28 MAb treatment, or unexposed
cells (n 38) were assessed for HIV-1 RNA using the Roche TaqMan assay (Roche) and Abbott RealTime HIV-1 assay (Abbott). HIV-1 RNA quantification was
performed using Roche TaqMan assay versus the Abbott RealTime HIV-1 assay in VOA culture supernatants obtained following anti-CD3/CD28 MAb treatment
(A) or treatment with vorinostat (B), romidepsin (C), panobinostat (D), givinostat (E), belinostat (F), or givinostat plus anti-CD3/CD28 MAbs (G). Panel H
shows the total results. (I) Correlation between HIV-1 RNA quantification using the Roche TaqMan assay and Abbott RealTime HIV-1. Histograms correspond
to the mean, and red error bars correspond to the SEM. NS, not significant. Statistical significance (P values) was obtained using Wilcoxon’s matched-pair
two-tailed signed rank test (A to H) or Spearman’s rank correlations (I).
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with HDACis compared to HDACi-untreated cell cultures (Fig.
1C and E). Interestingly, anti-CD3/CD28 and givinostat were able
to induce P24 in a higher proportion of subjects (i.e., 60 and 50%,
respectively) compared to the other HDACis, which induced P24
production in 10 to 30% of subjects (Fig. 1C). Compared to the
untreated cultures from the 10 subjects, the proportion of subjects
with positive P24 was significantly different (P  0.05) only for
anti-CD3/CD28- and givinostat-treated cultures (Fig. 1C). Along
the same line, the proportion of wells positive for P24 was signif-
icantly higher in anti-CD3/CD28 MAb- and givinostat-treated
cultures compared to the other HDACi-treated and -untreated
cultures (P 0.05) (Fig. 1E).
With regard to the levels of HIV-1 RNA and P24 measured in
the presence of the different HDACis, vorinostat and romidepsin
were less efficient at inducing HIV-1 RNA and P24 production
than panobinostat, givinostat, and belinostat, which induced lev-
els comparable to anti-CD3/CD28 MAb stimulation (Fig. 1F and
G). However, the proportions of P24 responders and P24-positive
wells were lower in panobinostat- versus givinostat-treated cul-
tures (Fig. 1C and E). All of the HDACis induced significantly
higher levels of HIV-1 RNA and P24 than untreated cell cultures
(P 0.05) (Fig. 1F and G).
Finally, the RUPM and IUPM frequencies were then calculated
for all conditions. The results indicate that RUPM frequencies
induced by all HDACis tested (i.e., vorinostat, romidepsin, pano-
binostat, givinostat, and belinostat) were significantly increased
compared to the frequencies under the unexposed conditions
(P 0.05) (Fig. 1H). However, the IUPM frequencies induced by
all HDACis tested (i.e., vorinostat, romidepsin, panobinostat,
givinostat, and belinostat) were not significantly increased (P 
0.05) (Fig. 1I).
We then determined the relationship between HIV-1 RNA and
P24. These analyses indicated that the levels of P24 production
correlated with HIV-1 RNA levels (r 0.59 and P 0.0001) (Fig.
1J). To determine whether HDACis could have differential effect
on HIV-1 RNA and P24 production, the levels of HIV-1 RNA and
P24 were plotted per treatment condition (Fig. 4A to F). The re-
sults obtained showed a direct correlation between P24 and HIV-1
RNA levels in all HDACis tested except following romidepsin ex-
posure (vorinostat, r  0.4293, P  0.0021; romidepsin, r 
0.1844, P  0.1998; panobinostat, r  0.7327, P  0.0001; givi-
nostat, r 0.8024,P 0.0001; belinostat, r 0.4845,P 0.0004),
suggesting that P24 production induced following HDACi treat-
ments was strongly associated with HIV-1 RNA levels.
Estimation of the proportion of provirus induced following
anti-CD3/CD28 MAb and HDACi treatments. Characterization
of full-length proviruses has illustrated that only 10 to 12% of
provirus was inducible, while only a fraction of the provirus was
induced following the VOA (29). To estimate the efficiency of
HDACis to reverse HIV-1 latency, the proportion of provirus in-
duced by HDACis among total provivus (Fig. 5A and B) or among
the proportion of provirus induced by anti-CD3/CD28 MAbs was
then estimated (Fig. 5C and D). The results indicate that only a
small fraction (	2.6%) of HIV-1 proviruses were reactivated to
produce virions, as assessed by HIV-1 RNA detection following
anti-CD3/CD28 MAbs and HDACis (Fig. 5A), supporting the re-
cent results of Cillo et al. (16). However, the fraction of HIV-1
proviruses induced by givinostat represented about 57% of that
induced by anti-CD3/CD28 MAb treatment and was significantly
higher than the fraction of HIV-1 proviruses induced by vorinos-
tat or romidepsin (Fig. 5B). The fraction of HIV-1 proviruses
reactivated to produce virions as assessed by HIV-1 P24 detection
following treatment with anti-CD3/CD28 MAbs and HDACis was
even lower and represented about 0.13% (Fig. 5C). However, the
fraction of HIV-1 proviruses induced by givinostat as assessed by
HIV-1 P24 detection represented about 74% of that induced by
anti-CD3/CD28 MAb treatment and was higher than the fraction
of HIV-1 proviruses induced by all of the other HDACis tested
(Fig. 5D), suggesting that givinostat is the most efficient HDACi
tested for reversing HIV-1 latency in vitro.
Infectivity of HIV-1 reactivated by HDACi treatment. The
presence of infectious virus in the culture supernatants of P24-
positive cell cultures was then assessed by analyzing the ability of
culture supernatants to transmit HIV-1 infection in vitro. Acti-
vated allogeneic CD8-depleted blood mononuclear cells from
HIV-1-uninfected donors were inoculated with supernatants col-
lected from P24-positive cell cultures (termed modified VOA su-
pernatants) of HIV-1-infected subjects for 6 h, and P24 produc-
tion was determined in the culture supernatants at days 3 and 10
postinoculation by ECL. Of note, P24 was never detected in all
culture supernatants at day 0. The cumulative data showed that
both the proportion of P24-positive wells and the levels of P24
significantly increased between days 3 and 10 (P  0.05) postin-
oculation, thus demonstrating that HIV isolated from the modi-
fied VOA cell cultures was infectious (Fig. 6A and B). Interest-
ingly, the P24 levels detected in the cell culture supernatants from
the new in vitro infection correlated with the P24 levels (r 
0.8417, P 0.0001) measured in the modified VOA supernatants
(Fig. 6C).
Assessment of potential synergistic effect between givinostat
treatment and TCR stimulation or PKC agonist on the reactiva-
tion of HIV-1 replication. To evaluate whether the HDACis and
TCR stimulation may synergize in the reactivation of HIV-1 rep-
lication, resting memory CD4 T cells isolated from aviremic long-
term-treated HIV-1-infected subjects known to be P24 positive
following givinostat treatment were exposed to givinostat or anti-
CD3/CD28 MAbs alone or in combination. The cumulative data
showed that neither the proportion of HIV-1 RNA/P24-positive
wells (Fig. 7A and B) nor the levels of HIV-1 RNA/P24 (Fig. 7C
and D) significantly increased upon the combined anti-CD3/
CD28 MAb– givinostat treatment (P  0.05). These results sug-
gested that both HDACis and TCR signals may target similar pop-
ulations of latently HIV-1-infected resting memory CD4 T cells.
The study by Laird et al. has recently demonstrated that com-
bination of mechanistically distinct LRAs may synergize to induce
HIV-1 transcription (18). To address whether givinostat may syn-
ergize with bryostatin (a protein kinase C [PKC] agonist), resting
memory CD4 T cells were isolated from 3 long-term-treated
aviremic HIV-infected subjects and cultured in the presence of
allogeneic CD8-depleted PBMCs. Cells were then exposed to givi-
nostat or bryostatin alone or in combination for 18 h. As an inter-
nal control, cells were also exposed to givinostat for 14 days. HIV
replication was assessed at day 14 of the VOA by the detection of
HIV-1 RNA and P24 in the culture supernatants. The cumulative
data showed that under all conditions tested viral replication was
significantly reactivated compared to under unstimulated culture
conditions, as assessed by the proportion of HIV-1 RNA/P24-
positive wells or by the levels of HIV-1 RNA/P24 (P 0.05) (Fig.
7E to H). Interestingly, the combined givinostat-bryostatin treat-
ment significantly increased the levels of HIV-1 RNA/P24 com-
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pared to cells exposed to givinostat alone for 18 h. However, the
levels of HIV RNA/P24 produced in the combined givinostat-
bryostatin treatment were not significantly higher than the levels
of HIV RNA/P24 produced in the culture supernatants of cells
exposed to bryostatin alone or those with prolonged/repeated ex-
posure to givinostat (P  0.05) (Fig. 7E to H). Taken together,
these results suggest that givinostat may synergize with mechanis-
tically different LRAs such as bryostatin. However, further inves-
tigations may be required.
Prolonged/repeated treatment of resting memory CD4 T
cells to HDACis is the primary mechanism responsible for effi-
cient induction ofHIV-1 replicationbyHDACi. Finally, we eval-
uated (i) the contribution of prolonged/repeated treatment (i.e.,
14 days) of resting memory CD4 T cells to HDACis and (ii) the
role of allogeneic CD8-depleted blood mononuclear cells in the
modified VOA as a source of potential target cells for HIV-1
and/or as the provider of an activation signal.
To address the first issue, resting memory CD4 T cells isolated
from aviremic long-term-treated HIV-1-infected subjects were
treated with givinostat for 18 h or 14 days in the presence of au-
tologous irradiated PBMCs. The use of autologous irradiated
CD8-depleted PBMCs prevented the increase of transcriptional
noise induced by mixed leukocyte reaction (MLR), and the fact
that the cells were irradiated prevented the amplification of the
virus through viral spreading. The results clearly indicate that the
treatment with givinostat for 14 days induced significantly higher
FIG 4 Correlation between P24 and HIV-1 RNA levels detected in culture supernatants following the viral outgrowth assay. Correlation between P24 and
HIV-1 RNA levels (n  50; 10 subjects, 5 replicates per condition) was obtained following anti-CD3/CD28 MAb treatment (A) or treatment with
vorinostat (B), romidepsin (C), panobinostat (D), givinostat (E), or belinostat (F). Each circle corresponds to one replicate, and each color corresponds
to one HIV-1-infected subject. Dotted lines correspond to the limit of detections. Statistical significance (P values) was obtained using Spearman’s rank
correlations.
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levels of HIV-1 RNA and P24 in the culture supernatants than in
the culture treated for 18 h (P 0.05) (Fig. 8A). Therefore, pro-
longed treatment with HDACis is a powerful strategy to break
HIV-1 latency in resting memory CD4 T cells from long-term
aviremic ART-treated patients in vitro.
With regard to the second issue, resting memory CD4 T cells
isolated from aviremic long-term-treated HIV-1-infected subjects
were treated with givinostat for 14 days in the presence of alloge-
neic irradiated or allogeneic nonirradiated CD8-depleted PBMCs,
and levels of HIV-1 RNA and P24 were compared to those found
in the cultures containing autologous irradiated CD8-depleted
PBMCs. In this context, the use of allogeneic irradiated CD8-
depleted PBMCs allowed the evaluation of the impact of the in-
crease of transcriptional noise induced by MLR and prevented the
amplification of the virus through viral spreading. Finally, the use
of allogeneic nonirradiated CD8-depleted PBMCs allowed the
evaluation of both the increase of transcriptional noise induced by
MLR and the signal amplification through viral spreading. No
significant differences (P  0.05) were observed in the levels of
HIV-1 RNA and P24 in the culture supernatants of cultures
treated with givinostat for 14 days in the presence of autologous or
allogeneic irradiated CD8-depleted PBMCs (Fig. 8A and B). These
results further confirm the importance of the prolonged treatment
of HDACis as the primary mechanism responsible for the induc-
tion of HIV-1 replication in resting memory CD4 T cells. How-
ever, a slight significant increase (P 0.05) in the levels of HIV-1
RNA and P24 was found in the culture supernatants of the alloge-
neic CD8-depleted nonirradiated PBMCs compared to autolo-
gous irradiated CD8-depleted PBMC cultures (Fig. 8A and B).
The results suggested that using allogeneic CD8-depleted nonir-
radiated PBMCs may be associated with some degree of cell acti-
vation that can influence the amplification of HIV in the cell cul-
tures. In this regard, it was observed that the use of allogeneic
nonirradiated CD8-depleted PBMCs was associated with a mod-
erate increase in the percentage of activated and proliferating CD4
T cells, as assessed by CD25 and HLA-DR expression (5.1% versus
0.8% and 3.5% versus 0.4% at day 3 in the allogeneic nonirradi-
ated and allogeneic irradiated cell cultures, respectively) (Fig. 9)
and by CFSE-based assay (5.1% versus 0.8% at day 6; P  0.05)
(Fig. 9).
DISCUSSION
Systematic preclinical evaluation of potential LRAs in primary
CD4 T cells isolated from HIV-infected individuals on ART rep-
resents a fundamental step to advance toward clinical trials. Evi-
dence that LRAs reactivate HIV-1 replication from primary rest-
ing memory CD4 T cells isolated from aviremic long-term-treated
HIV-1-infected subjects is limited and remains challenging, while
recent clinical trials based on vorinostat, romidepsin, and pano-
binostat performed in HIV-1 patients under ART showed modest
FIG 5 Estimation of the proportion of provirus induced following treatment with anti-CD3/CD28 MAbs and HDACis. (A) Proportion of provirus
induced following treatments with anti-CD3/CD28 MAbs and HDACis as assessed by the ratio of RUPM and integrated (INT) DNA (n  10). (B)
Proportion of provirus induced following treatment with anti-CD3/CD28 MAbs and HDACis as assessed by the ratio of IUPM and integrated DNA (n
10). (C) Proportion of provirus induced following HDACi treatment compared to treatment with anti-CD3/CD28 MAbs as assessed by RUPM. (D)
Proportion of provirus induced following treatment with HDACis compared to anti-CD3/CD28 MAbs as assessed by IUPM (n 6). Red asterisks indicate
statistical significance (P  0.05). Statistical significance (P values) was obtained using one-way ANOVA (Kruskal-Wallis test) followed by Wilcoxon’s
matched-pair two-tailed signed rank test.
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but encouraging effects (20, 26; O. S. Sogaard, presented at AIDS
2014: 20th International AIDS Conference, Melbourne, Australia
[www.aids2014.org]).
In the present study, we hypothesized that increasing the du-
ration of exposure of resting memory CD4 T cells to HDACis may
result in efficient induction and amplification of HIV-1 replica-
tion in resting memory CD4 T cells of aviremic long-term-treated
HIV-1-infected subjects in vitro. The bulk of the data presented in
Fig. 1, 3, 4, and 5 were generated using a 14-day treatment of
cultures with the different HDACis in combination with alloge-
neic nonirradiated CD8-depleted PBMCs. The individual contri-
butions of the modifications implemented in the newly developed
VOA were also assessed.
The presence of HIV-1 RNA and P24 was measured in VOA
culture supernatants using validated diagnostic assays and al-
lowed the assessment of (i) the proportion of responders, (ii) the
proportion of positive wells, (iii) the levels of HIV-1 RNA and
P24, and (iv) the RUPM and IUPM frequencies, as well as (v)
determination of the proportion of provirus induced following
anti-CD3/CD28 MAb and HDACi treatments. The results first
indicated that the signal induced by allogeneic stimulation was not
sufficient to induce HIV-1 replication, as assessed by HIV-1 RNA
and P24 detection in the culture supernatants, since all replicates
(except one at the limit of detection) of the unstimulated condi-
tion remained negative for both HIV-1 RNA and P24. Interest-
ingly, the results indicated that vorinostat and romidepsin were
less efficient at inducing HIV-1 RNA and P24 production than
panobinostat, givinostat, and belinostat. Of note, the results ob-
tained with panobinostat mirror the results obtained in vivo by
Rasmussen et al., which showed that repeated exposure to pano-
binostat effectively disrupts HIV-1 latency in vivo (20). Interest-
ingly, givinostat was more efficient at inducing P24 production
than vorinostat, panobinostat, and romidepsin at reversing HIV-1
latency in vitro.
Characterization of full-length proviruses has illustrated that
only 10 to 12% of proviruses were inducible, while only a fraction
of them were induced following VOA (29). Interestingly, the re-
activated provirus induced by givinostat represented 57 to 74% of
that induced by anti-CD3/CD28 MAb treatment and was signifi-
cantly higher than the fraction of HIV-1 proviruses induced by
vorinostat or romidepsin. In addition, the combined treatment
of resting CD4 T cells with givinostat and anti-CD3/CD28
MAbs did not significantly increase HIV-1 replication com-
pared to givinostat treatment alone, suggesting that givinostat
and TCR signals may target similar populations of latently
HIV-1-infected resting memory CD4 T cells and confirmed the
proportion of reactivated provirus induced by givinostat. Sim-
ilarly, the combined treatment of resting CD4 T cells with givi-
nostat and bryostatin (a PKC agonist) did not significantly
increase HIV-1 replication compared to bryostatin treatment
alone, suggesting that givinostat may synergize with mechanis-
tically different LRAs such as bryostatin. However, further in-
vestigations may be required.
Of note, givinostat has not been evaluated in an HIV clinical
FIG 6 Infectivity of HIV-1 reactivated by HDACi treatment. (A) Proportion of P24-positive wells at days 3 and 10 after in vitro HIV-1 inoculation of activated
allogeneic CD8-depleted mononuclear cells from HIV-1-negative subjects in the modified VOA culture supernatants (obtained from P24-positive supernatants
at day 14) (n 27). (B) P24 values at days 3 and 10 following in vitro HIV-1 infection (n 27). (C) Correlation between P24 levels detected in the cell culture
supernatants from the in vitro infection assay and the P24 levels of the modified VOA supernatants (n  27). Subjects were color coded, and each color
corresponds to a subject (B and C). Each condition is depicted with a unique symbol. Red asterisks indicate statistical significance (P  0.05). Statistical
significance (P values) was obtained using two-tailed chi-square analysis for comparison of positive proportions (A), Wilcoxon’s matched-pair two-tailed signed
rank test (B), or Spearman’s rank correlations (C).
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FIG 7 Assessment of potential synergistic effect between givinostat treatment and TCR stimulation or PKC agonist on the reactivation of HIV-1 replication. (A)
Proportion of HIV-1 RNA-positive wells following treatment with givinostat and/or anti-CD3/CD28 MAbs (n 4). Wells with detectable HIV-1 RNA (200
HIV-1 RNA copies/ml) are indicated as HIV-1 RNA-positive wells for the condition tested. (B) Proportion of P24-positive wells following treatment with
givinostat and/or anti-CD3/CD28 MAbs (n 4). Wells with detectable P24 (1 ECL unit/ml) are indicated as P24 positive for the condition tested. (C) HIV-1
RNA (copies per milliliter) induced following treatment with givinostat and/or anti-CD3/CD28 MAbs (n  4). (D) Levels of P24 (ECL units per milliliter)
induced following treatment with givinostat and/or anti-CD3/CD28 MAbs (n  4). (E) Proportion of HIV-1 RNA-positive wells following treatment with
anti-CD3/CD28 MAbs or givinostat (Givi) and/or bryostatin (Bryo) (n 3). Wells with detectable HIV-1 RNA (200 HIV-1 RNA copies/ml) are indicated as
HIV-1 RNA-positive wells for the condition tested. US, unstimulated. (F) Proportion of P24-positive wells following treatment with anti-CD3/CD28 MAbs or
givinostat and/or bryostatin (n 3). Wells with detectable P24 (1 ECL unit/ml) are indicated as P24-positive wells for the condition tested. (G) Levels of HIV-1
RNA copies per milliliter induced following treatment with anti-CD3/CD28 MAbs or givinostat and/or bryostatin (n 3). (H) Levels of HIV-1 P24 (ECL units
per milliliter) induced following treatment with anti-CD3/CD28 MAbs or givinostat and/or bryostatin (n  3). Subjects were color coded, and each color
corresponds to a subject (C and D and G and H). Red error bars correspond to means
 SEM. Red asterisks indicate statistical significance (P 0.05). Green
asterisks indicate statistical significance compared to the givinostat (18-h) condition (P 0.05). Statistical significance (P values) was obtained using two-tailed
chi-square analysis for comparison of positive proportions (A, B, E, and F) or by one-way ANOVA (Kruskal-Wallis test) followed by Wilcoxon matched-pair
two-tailed signed rank test (C, D, G, and H).
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trial but is currently being evaluated in a phase II clinical trial for
leukemia and has been approved by the European Union for treat-
ment of juvenile arthritis since 2010 (30). Givinostat has been
shown to be safe upon single or repeated oral dose administration,
is eliminated slowly (half-life of 6 to 7 h), and shows robust dose-
dependent pharmacokinetics up to a dose of 600 mg daily, achiev-
ing a maximum concentration of 542
 93 ng/ml in the blood of
healthy individuals. Similar to its short-term use, there have been
no adverse effects associated with long-term use of givinostat (30).
Its administration has been associated with mild but reversible
effects on platelet and neutrophil levels in blood and with a tran-
sient decrease in the levels of proinflammatory cytokine produc-
tion (30).
We have also demonstrated that HIV-1 reactivated in the
VOA cell culture supernatants was not only replication com-
petent but also infectious using an in vitro HIV-1 infection
assay. In addition, the P24 levels detected in the cell culture
supernatants from the new in vitro infection correlated with the
P24 levels measured in the modified VOA supernatants regard-
less of the original VOA treatment, thus suggesting that the
presence of infectious particles was directly associated with the
efficiency of the reactivation.
Finally, we have evaluated the contribution of the parameters
modified in the present VOA: i.e., (i) prolonged/repeated HDACi
treatment and (ii) use of allogeneic CD8-depleted blood mono-
nuclear cells as a provider of an activation signal and/or as a source
of de novo CD4 T-cell targets for HIV-1. We provide evidence that
the prolonged treatment with HDACis is the primary mechanism
responsible for the reactivation of HIV-1 replication in resting
memory CD4 T cells of aviremic long-term-ART-treated patients.
The use of allogeneic nonirradiated blood mononuclear cells ap-
pears to have a secondary effect since it was associated with only a
moderate increase in the percentage of activated CD4 T cells and a
minor effect on HIV-1 replication.
In summary, the present modified VOA represents a powerful
tool in order to evaluate consistently the potency of novel LRAs
and/or combination therapies to reactivate HIV-1 replication in
resting memory CD4 T cells of long-term-treated aviremic HIV-1
infected subjects. Using this assay, we demonstrated that pro-
longed/repeated treatment of resting memory CD4 T cells with
HDACis induced HIV-1 replication and production from pri-
mary resting memory CD4 T cells isolated from aviremic long-
term-treated HIV-1-infected subjects. Interestingly, the viral par-
ticles produced were not only replication competent but also
infectious. Notably, givinostat, an HDACi that has not been inves-
tigated in clinical trials, was more efficient than vorinostat, pano-
binostat, and romidepsin in reversing HIV-1 latency in vitro. The
reason why givinostat harbors enhanced efficacy of latency rever-
sal in vitro remains to be established. However, the fact that givi-
nostat was used at a higher concentration (i.e., 400 nM) than
panobinostat and romidepsin might have contributed to its en-
hanced in vitro efficacy of latency reversal. Indeed, the concentra-
tions of panobinostat and romidepsin used in our experimental
settings were about 26- and 80-fold lower than that of givinostat.
Of note, all HDACis were used at clinically relevant concentra-
tions.
Taken together, these results support further evaluation of
givinostat as a latency-reversing agent in aviremic long-term-
treated HIV-1-infected subjects.
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